1 / 24

Community Pharmacists: A Forgotten Resource for Palliative Care

Community Pharmacists: A Forgotten Resource for Palliative Care. Paul Tait , John Gray, Paul Hakendorf, Bel Morris, David Currow & Debra Rowett. Aim. Identify likelihood of community pharmacies having medicines for symptom control in the terminal p hase

taariq
Télécharger la présentation

Community Pharmacists: A Forgotten Resource for Palliative Care

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Community Pharmacists: A Forgotten Resource for Palliative Care Paul Tait, John Gray, Paul Hakendorf, Bel Morris, David Currow & Debra Rowett

  2. Aim • Identify likelihood of community pharmacies having medicines for symptom control in the terminal phase • Identify community pharmacy’s level of awareness of palliative patients/carers • Understand the demographics of the community pharmacies • Develop a distribution list of community pharmacies Building a platform for improved access to palliative medicines in the community

  3. Terminal Phase Medicines (TPM) List • Symptoms: • Dyspnoea • Pain • Nausea • Delirium ± agitation; and • Noisy secretions. • Physical ability • decreased energy levels; • reduced ability to swallow; and • impaired mental state Building a platform for improved access to palliative medicines in the community

  4. Terminal Phase Medicines (TPM) List Building a platform for improved access to palliative medicines in the community

  5. TPM List • Clonazepam 1mg inj* • Clonazepam 2.5mg/mL oral drops* • Dexamethasone 4mg/mL inj* • Fentanyl 100mcg/2mL inj • Haloperidol 5mg/mL inj* • Hydromorphone 10mg/mL inj* • Hyoscine Butylbromide 20mg/mL inj* • Hyoscine Hydrobromide 400mcg/mL inj • Metoclopramide 10mg/2mL inj* • Midazolam 5mg/mL inj • Morphine 10mg/mL inj* • Morphine 10mg/mL oral mixture* • Oxycodone 10mg/mL inj Building a platform for improved access to palliative medicines in the community

  6. The Survey • Demographics of the pharmacy • Role of the person completing the survey; • Postcode (→socioeconomic scales, rural/metro); • Pharmacist FTEs; • Usual opening hours; and • Clinical and supply services offered. • Awareness of palliative patients • How many palliative patients had used pharmacy over the previous 12 months; • How they became aware of palliative status; and • The range of issues affecting timely access to these medicines. Building a platform for improved access to palliative medicines in the community

  7. The Survey • Access to stock • Date of completing the survey; • Existence of medicines from the TPM List in their dispensary; and • Shortest expiry date of each item held within the pharmacy. • Willingness to be part of an email distribution list Building a platform for improved access to palliative medicines in the community

  8. Methodology • Southern Adelaide Clinical Human Research Ethics Committee (SAC HREC) • Each community pharmacy was allocated an individual code. • Survey was mailed with a cover letter to 455 pharmacies across SA • All responding pharmacies were allocated to a decile of the Seifa Index • No reminders were sent out Building a platform for improved access to palliative medicines in the community

  9. Likelihood Of Having Stock Building a platform for improved access to palliative medicines in the community

  10. Likelihood Of Having Stock Building a platform for improved access to palliative medicines in the community

  11. Likelihood Of Having Stock Building a platform for improved access to palliative medicines in the community

  12. Likelihood Of Having Stock Building a platform for improved access to palliative medicines in the community

  13. Likelihood Of Having Stock Building a platform for improved access to palliative medicines in the community

  14. Likelihood Of Having Stock Building a platform for improved access to palliative medicines in the community

  15. Awareness Building a platform for improved access to palliative medicines in the community

  16. Awareness Building a platform for improved access to palliative medicines in the community

  17. Expiry Date Data Building a platform for improved access to palliative medicines in the community

  18. Recommendations • Prescribers: • Involve community pharmacists in discussions about care planning • Palliative Care Organisations: • Develop a core medicines list to guide prescribers and community pharmacists alike • Policy Makers: • Create incentives for community pharmacies to hold a small range of medicines Building a platform for improved access to palliative medicines in the community

  19. Reflections What Worked Well What We’d Do Differently Enquiring about a single strength for each medicine may have skewed data • Sending survey in paper form with reply paid envelope • Surveying all pharmacies across SA • Asking about expiry dates • Choice of medicines matched the WA essential medicines document Building a platform for improved access to palliative medicines in the community

  20. Community Pharmacists: A Forgotten Resource for Palliative Care Paul Tait, John Gray, Paul Hakendorf, Bel Morris, David Currow & Debra Rowett

  21. Core Medicines For noncomplex adult patients • Clonazepam 1mg injection; • Morphine 10mg/mL injection; • Haloperidol 5mg/mL injection; • Metoclopramide 10mg/2mL injection; • Hyoscine butylbromide 20mg/mL injection. Building a platform for improved access to palliative medicines in the community

  22. Demographics Building a platform for improved access to palliative medicines in the community

  23. Issues Building a platform for improved access to palliative medicines in the community

  24. Building a platform for improved access to palliative medicines in the community

More Related